Online inquiry

IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7900MR)

This product GTTS-WQ7900MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MAG gene. The antibody can be applied in Stroke research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001199216.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4099
UniProt ID P20916
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7900MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1955MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ8427MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ7368MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ11980MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ7219MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ11145MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ225MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ8734MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuPRO-140
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW